B7‑H3 (CD276): Dissecting a Context‑Dual Immune Checkpoint for Tumour‑Immunology Research

Molecular Architecture and Dual Immunoregulatory Characteristics of B7‑H3

Full T‑cell activation requires two distinct signal inputs originating from MHC‑peptide‑TCR complexes and B7‑family co‑regulatory molecules. B7‑H3, also designated CD276, belongs to the B7‑CD28 superfamily and exhibits conflicting functional observations across different experimental systems. Human B7‑H3 gene maps to chromosome 15q24.1 and generates a primary 4.1 kb mRNA transcript for protein translation.

This type‑I transmembrane glycoprotein carries an N‑terminal signal peptide, extracellular IgV‑IgC domains, a transmembrane helix and a short intracellular cytoplasmic tail. Exon‑duplication events produce two human splice isoforms: 2Ig‑B7‑H3 and the predominant 4Ig‑B7‑H3 variant. Murine B7‑H3 exists only as the 2Ig isoform and shares 88 % sequence identity with its human orthologue.

Early in‑vitro co‑culture assays documented costimulatory activity that promotes CD4⁺ and CD8⁺ T‑cell proliferation alongside elevated IFN‑γ and IL‑12 secretion. Subsequent experimental datasets support predominant co‑inhibitory capacity through suppression of NFAT, AP‑1 and NF‑κB transcriptional activity. Reduced IL‑2 transcription restrains T‑cell effector functions under these assay conditions.

B7‑H3 exerts uneven effects across helper‑T‑cell subsets, dampening Th1‑associated outputs yet enhancing Th2‑ and Th17‑type cytokine production. Such polarizing effects have drawn research interest for in‑vitro autoimmunity‑relevant model systems. Most academic frameworks categorize B7‑H3 as a co‑inhibitory checkpoint, though costimulatory readouts cannot be fully dismissed. Functional duality may stem from isoform variation, microenvironmental cytokines and incompletely characterized receptor networks; TLT2 remains one proposed putative receptor.

Expression Patterns and Downstream Signalling Outputs in Tumour‑Model Systems

B7‑H3 mRNA transcripts can be detected across multiple normal tissue specimens including liver, small intestine, pancreas and colon, yet protein expression stays tightly controlled at post‑transcriptional levels. Quiescent immune cells maintain very low surface B7‑H3 abundance, while stimulation with GM‑CSF or LPS drives notable protein up‑regulation on B‑cells, T‑cells, monocytes and NK‑cells.

Multiple solid‑tumour experimental samples display marked B7‑H3 over‑expression, correlating with advanced disease stage, higher histological grade and enhanced invasive phenotypes in many tumour types. Soluble circulating sB7‑H3 isoforms can also be recovered from cell‑culture supernatants and experimental serum specimens, capable of triggering NF‑κB‑driven signalling cascades.

Notably, prognostic correlations are not universally consistent across all tumour backgrounds. Certain gastric and pancreatic tumour‑derived datasets link higher B7‑H3 abundance to extended survival readouts. Such divergent observations reflect tumour heterogeneity, variable sampling criteria and differences in detection methodologies used across independent research groups.

Beyond immune‑modulatory roles, B7‑H3 engages intracellular signalling modules including PI3K‑AKT‑STAT3, JAK2‑STAT3 and NF‑κB axes within tumour‑cell lines. These cascades support cell survival, epithelial‑mesenchymal transition and pro‑angiogenic mediator release. B7‑H3 can also shape epigenetic landscapes by modifying chromatin‑remodelling‑enzyme activity within malignant cell populations. Net biological outputs remain heavily dependent on cellular context and surrounding microenvironment components.

Pre‑Clinical Research Modalities Targeting B7‑H3 and Remaining Technical Barriers

Multiple experimental intervention strategies have been developed to explore B7‑H3‑directed anti‑tumour effects in pre‑clinical setups. Fc‑engineered monoclonal antibody constructs such as Enoblituzumab (MGA271) leverage ADCC‑mediated effector functions without strict reliance on ligand‑receptor blockade. Radioisotope‑conjugated antibody formats, ADC platforms and B7‑H3‑redirected CAR‑T constructs constitute additional active research avenues.

B7‑H3‑targeted CAR‑T preparations have produced measurable anti‑tumour effects in multiple xenograft‑model systems, including paediatric solid‑tumour derived samples. Pure blocking‑type monoclonal‑antibody candidates remain confined to early‑stage research due to incomplete knowledge regarding functional inhibitory receptor identities.

Several major obstacles slow translational progress for B7‑H3‑oriented projects. Unidentified inhibitory‑receptor molecules limit rational antagonist design workflows. Context‑shifting biological effects demand careful re‑evaluation within each distinct tumour‑model background. Standardized immunohistochemistry scoring criteria for biomarker evaluation still require multi‑centre validation work. Rational combinatorial regimens paired with checkpoint modulators, cytotoxic agents or radiation also need systematic laboratory assessment.

Detection Reagent Resources from ANT BIO PTE. LTD. for B7‑H3‑Related Basic Research

Reliable detection antibodies constitute fundamental tools for B7‑H3 expression profiling, biomarker‑oriented analysis and mechanism‑focused laboratory investigations. ANT BIO PTE. LTD. supplies recombinant rabbit monoclonal anti‑B7‑H3 antibody clones for multi‑platform immuno‑assay workflows.

B7‑H3 Recombinant Rabbit mAb (SDT‑249‑26) and clone SDT‑1333‑8 support immunohistochemistry, flow cytometry and western‑blot experimental setups. Rigorous quality‑control workflows preserve batch‑to‑batch consistency for long‑term serial research campaigns. Researchers deploy these reagents to quantify B7‑H3 protein abundance in tissue sections and cell lysates during tumour‑immunology and pre‑clinical drug‑evaluation projects.

Related Product Portfolio

ANT BIO PTE. LTD. – Empowering Scientific Breakthroughs
At ANTBIO, we are committed to advancing life science research through high‑quality, reliable reagents and comprehensive solutions. Our specialized sub‑brands (Absin, Starter, UA) cover a full spectrum of research needs, from general reagents and kits to antibodies and recombinant proteins. With a focus on innovation, quality, and customer‑centricity, we strive to be your trusted partner in unlocking scientific mysteries and driving medical progress. Explore our product portfolio today and elevate your research to new heights.

Disclaimer
This article was partially created with the assistance of artificial intelligence. If any content involves copyright or intellectual property issues, please inform us, and we promise to verify and remove it immediately.